177 results on '"Schreiber, Taylor H."'
Search Results
2. Shining a LIGHT on myeloid cell targeted immunotherapy
3. Data from Lipid-Encapsulated mRNAs Encoding Complex Fusion Proteins Potentiate Antitumor Immune Responses
4. Lipid-encapsulated mRNAs encoding complex fusion proteins potentiate anti-tumor immune responses
5. Reconciling intrinsic properties of activating TNF receptors by native ligands versus synthetic agonists
6. Parallel Costimulation of Effector and Regulatory T Cells by OX40, GITR, TNFRSF25, CD27, and CD137: Implications for Cancer Immunotherapy
7. Reversal of indoleamine 2,3-dioxygenase–mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme
8. Supplementary Data from CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity
9. Data from CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity
10. Abstract 1815: Rapid serial killing of target cells by Vγ9Vδ2 T Cells in cynomolgus macaques and humanized mice treated with a CD20-directed heterodimeric butyrophilin 2A1/3A1 fusion protein
11. Supplementary Figure Legends from Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination
12. Supplemental Figure 1 from Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination
13. Supplemental Figure 4 from Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination
14. Data from Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination
15. Supplemental Figure 3 from Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination
16. Supplemental Figure 5 from Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination
17. Supplemental Figure 2 from Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination
18. The Role of B Cells in Shaping the Antitumor Immune Response
19. Heat-Shock Protein-Based Cancer Immunotherapy
20. Supplementary Figure Legends 1-2 from Tumor-Induced Suppression of CTL Expansion and Subjugation by gp96-Ig Vaccination
21. Data from Tumor-Induced Suppression of CTL Expansion and Subjugation by gp96-Ig Vaccination
22. Supplementary Figure 1 from Tumor-Induced Suppression of CTL Expansion and Subjugation by gp96-Ig Vaccination
23. Supplementary Figure 2 from Tumor-Induced Suppression of CTL Expansion and Subjugation by gp96-Ig Vaccination
24. The Role of TNFRSF25:TNFSF15 in Disease… and Health?
25. Cutting Edge: Bispecific γδ T Cell Engager Containing Heterodimeric BTN2A1 and BTN3A1 Promotes Targeted Activation of Vγ9Vδ2+ T Cells in the Presence of Costimulation by CD28 or NKG2D
26. Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
27. LIGHT (TNFSF14) Costimulation Enhances Myeloid Cell Activation and Antitumor Immunity in the Setting of PD-1/PD-L1 and TIGIT Checkpoint Blockade
28. Abstract 4214: LIGHT (TNFSF14) costimulation with TIGIT blockade broadens the activity of checkpoint inhibitors (CPIs) into CPI refractory and resistant tumors through targeted myeloid cell and effector lymphocyte activation
29. Abstract 3514: Bispecific gamma delta T cell engagers containing butyrophilin 2A1/3A1 heterodimeric fusion protein efficiently activate Vg9Vd2 T cells and promote tumor cell killing
30. Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1α-dependent and extracellular adenosine-mediated tumor protection
31. Disruption of polycystin-L causes hippocampal and thalamocortical hyperexcitability
32. Tumor immunogenicity and responsiveness to cancer vaccine therapy: The state of the art
33. Host CD4+CD25+ T cells can expand and comprise a major component of the Treg compartment after experimental HCT
34. Immunobiology of TNFSF15 and TNFRSF25
35. Secreted heat shock protein gp96-Ig: next-generation vaccines for cancer and infectious diseases
36. B lymphocyte inhibition of anti-tumor response depends on expansion of Treg but is independent of B-cell IL-10 secretion
37. Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer
38. Abstract 1736: Antigen-specific targeting of tissue-resident gamma delta T cells with recombinant butyrophilin heterodimeric fusion proteins
39. Abstract 1697: The development of an in vivo model of checkpoint acquired resistance, reveals a program of interferon hyperstimulation, resulting in dysregulation of MHC class I, protein translation/trafficking, and other unique pathways, that may be useful for guiding clinical strategy in patients with phenotypic similarities
40. Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer
41. Therapeutic Treg expansion in mice by TNFRSF25 prevents allergic lung inflammation
42. Heat-Shock Protein-Based Cancer Immunotherapy
43. The Role of B Cells in Shaping the Antitumor Immune Response
44. Shear flow–dependent integration of apical and subendothelial chemokines in T-cell transmigration: implications for locomotion and the multistep paradigm
45. The Role of TNFRSF25:TNFSF15 in Disease… and Health?
46. Response to Taraban, Ferdinand, and Al-Shamkhani
47. CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity
48. Abstract 2271: Development and characterization of SL-115154 (CSF1R-Fc-CD40L) for cancer immunotherapy
49. Identification and Characterization of a Novel Polycystin Family Member, Polycystin-L2, in Mouse and Human: Sequence, Expression, Alternative Splicing, and Chromosomal Localization
50. Abstract 5564: Agonist redirected checkpoint, VSIG8-Fc-OX40L, for cancer immunotherapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.